Inflammatory bowel disease drug efficacy screening process
By inducing the differentiation of pluripotent stem cells into colonic organoids with functional macrophages, a screening process for inflammatory bowel disease was established, which solved the problem of insufficient model correlation in the existing technology, and achieved inflammatory bowel in vitro Accurate simulation of diseases and drug efficacy screening have improved the success rate and R&D efficiency of new drug development.
Patent Information
- Application Number
- CN202410831236.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-26
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-06-26
AI Technical Summary
In the development of existing inflammatory bowel disease drugs, there are insufficient physiological correlations and differences in species between cell models and animal models, resulting in a low success rate of drug development and lack of effective ability to accurately simulate inflammatory bowel disease in vitro and perform drug efficacy screening. Model.
By inducing the differentiation of pluripotent stem cells into colonic organoids with functional macrophages, a drug effect screening process for inflammatory bowel disease containing macrophages is established, and the drug effect screening of IBD is used to inhibit the inflammatory response. Drug efficacy evaluation was conducted by restoring mucus content and repairing damaged barriers.
Accurate simulation and drug efficacy screening in vitro inflammatory bowel disease are achieved, the success rate of new drug development is improved, the R&D cycle is shortened, and a more physiologically relevant drug efficacy screening model is provided.
Smart Images

Figure CN118389634B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of induced pluripotent stem cells, and in particular to a drug efficacy screening process for inflammatory bowel disease. Background Art
[0002] Inflammatory bowel disease (IBD) is a chronic immune disease that includes two subtypes: ulcerative colitis (UC) and Crohn's disease (CD). According to incomplete statistics, as of 2023, the number of IBD patients worldwide has exceeded 10 million. However, the pathological mechanism of IBD is still unclear, and there is no cure; once the disease occurs, patients often require lifelong treatment, and the cost of care often continues to increase as the pathology progresses. Therefore, it is urgent to develop more effective treatment strategies.
[0003] Due to the difficulty in obtaining primary human intestines, cell models and animal models have long been the main models for preclinical efficacy evaluation of IBD. A large amount of data has shown that the lack of physiological relevance of cell models and the natural shortcomings of animal models in species differences are important reasons for the low success rate of current drug development (only about 7.8%). Developing a human-derived efficacy screening model with strong physiological relevance has become a common goal of academia and industry.
[0004] In recent years, with the rapid development of stem cell biology and tissue engineering, organoid technology has emerged. Compared with traditional cell models, organoids have better cell diversity, structural multi-lineage and functional specificity, which can make up for the shortcomings of traditional cell models and animal models. At present, the induction differentiation technology of colon organoids from human adult stem cells (hASC, human adult stem cell) and human pluripotent stem cells (hPSC, human pluripotent stem cell) has been successfully established; but no matter which type, they only contain intestinal epithelial cells, but lack other supporting cell types, such as macrophages, an important cell type that mediates inflammatory responses in IBD. If there is a colon organoid that has macrophages on the basis of different epithelial cell types, it is expected to achieve accurate simulation and drug efficacy screening of IBD in vitro. Summary of the invention
[0005] In view of this, the present invention aims to provide an inflammatory bowel disease drug efficacy screening process, which establishes a complete IBD drug efficacy screening process based on colon organoids with functional macrophages. The process can evaluate and screen IBD drug efficacy through multiple pathological indicators such as inhibiting inflammatory response, restoring mucus content, and repairing damaged barriers. It is suitable for the precise preclinical evaluation of IBD candidate drugs to improve the success rate of new drug development and shorten the R&D cycle.
[0006] To achieve the above object, the technical solution of the present invention is implemented as follows:
[0007] A process for screening drug efficacy for inflammatory bowel disease, the process comprising the following steps:
[0008] 1) Construction of macrophage-containing colon organoids
[0009] Induce pluripotent stem cells to differentiate into the middle and posterior derivatives of the intestinal tube with hematopoietic progenitor cells, then select the lower layer 2D cells for mechanical disruption, and then encapsulate them in Matrigel and use medium 3a and medium 3b to continue differentiation to form colon organoids;
[0010] The obtained organoids were then transferred to EP tubes and mechanically broken, and then coated with matrix gel again, and then pre-cultured with culture medium 3a, and then continued to be cultured with culture medium 3b, and subcultured every 7-10 days at a ratio of 1:5-1:10; the expanded and cultured organoids were then tested to verify that the organoids contained colon epithelial cells, mesenchymal cells, and intestinal resident macrophages;
[0011] 2) IBD modeling and testing
[0012] A control group and a modeling group were set up, and then PBS and DSS were added to the culture medium of the control group and the modeling group respectively to treat the modeling. The expression level of IBD pathological markers was detected and analyzed using the fluorescent quantitative Q-PCR method to verify the success of the modeling;
[0013] 3) IBD drug efficacy screening
[0014] A drug group was set up, that is, the test drug was added to the culture medium of the tested model group, and the treatment was continued for 3-7 days. The IBD efficacy was evaluated by detecting one or more of the inhibition of inflammatory response, restoration of mucus content, and repair of damaged barriers. When the P value between groups was <0.05, it was determined that there was an IBD efficacy.
[0015] Furthermore, in step 1), the organoids are characterized by flow cytometry or immunofluorescence staining to confirm lineage diversity.
[0016] Furthermore, the flow cytometry method is as follows: the amplified product is digested and dispersed into single cells using TrypLE, and fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton, and blocked with 5% normal donkey serum. Thereafter, the cell number is analyzed using a flow cytometer after labeling and staining based on specific marker antibodies.
[0017] The immunofluorescence staining method is: fix with 4% paraformaldehyde, permeabilize with 0.1% Triton, block with 5% normal donkey serum, then label and stain with specific marker antibodies, and take pictures with a laser confocal microscope.
[0018] Furthermore, the mass concentration of DSS used in step 2) is 0.005-0.015%, and the treatment time is 4-6 days.
[0019] Furthermore, in step 2), 30-50 organoids / well × 3-5 replicate wells were inoculated in both the control group and the modeling group; in addition, 3-5 additional replicate wells were set up for both groups for model quality verification.
[0020] Furthermore, the IBD pathological markers in step 2) include the epithelial marker β-CAT, the inflammatory factor TNF-α and the mucin marker MUC2.
[0021] Furthermore, IBD pathological markers were evaluated as follows:
[0022] 1) Epithelial to mesenchymal transition: When β-CAT expression is significantly reduced, that is, the inter-group P value is less than 0.05, it indicates that the epithelial barrier is damaged;
[0023] 2) Increased inflammation level: When TNF-α expression is significantly increased, that is, the inter-group P value is less than 0.05, it indicates that the inflammation level is increased;
[0024] 3) Decreased mucus level: When MUC2 expression is significantly reduced, that is, the P value between groups is less than 0.05, it indicates that the mucus level is reduced;
[0025] When the above three evaluations showed statistical differences among the groups, the model was considered to have passed the quality test.
[0026] Furthermore, the evaluation of IBD drug efficacy specifically includes the following:
[0027] 1) The evaluation method for inhibiting inflammatory response is as follows: the organoids of the control group, model group, and drug group are taken, and the secretion of IBD-related inflammatory factors in the supernatant is detected by ELISA enzyme-linked immunosorbent assay. When the inflammatory factors in the drug group are significantly less than those in the model group, that is, the inter-group P value is <0.05, it is considered to be effective in inhibiting inflammation;
[0028] 2) The evaluation method for restoring mucus content is: analyzing the mucus content by PAS pathological section staining, and using ImageJ software for quantitative analysis based on the staining area; when the PAS staining positive area in the drug group is significantly less than that in the modeling group, that is, the inter-group P value is <0.05, it is considered to be effective in mucus recovery;
[0029] 3) The evaluation method for repairing the damaged barrier is: detecting the β-CAT positivity rate by staining pathological sections and using ImageJ software for quantitative analysis; when the β-CAT staining positive area in the drug group is significantly higher than that in the modeling group, that is, the inter-group P value is <0.05, it is considered to be effective in barrier repair.
[0030] Furthermore, the inflammatory factors include one or more of TNF-α, IL-6, IL-23, and IL-33.
[0031] Further, in step 1), the organoids are pre-cultured in culture medium 3a for 1-2 days after mechanical disruption; culture medium 3a includes BMP2, EGF, Wnt / β-CAT activator and StemPro-34, and culture medium 3b includes EGF, BMP inhibitor, Wnt / β-CAT activator, VEGF, M-CSF and StemPro-34.
[0032] Furthermore, the concentration of BMP2 was 50-150 ng / ml, the concentration of EGF was 50-150 ng / ml, the concentration of Wnt / β-CAT activator was 2-4 μM, the concentration of BMP inhibitor was 100-250 nM, the concentration of VEGF was 10-20 ng / ml, and the concentration of M-CSF was 10-20 ng / ml; the volume ratio of StemPro-34 in culture medium 3a was 21.25%-42.5%, and the volume ratio in culture medium 3b was 17.5-35%.
[0033] Compared with the prior art, the inflammatory bowel disease drug efficacy screening process of the present invention has the following advantages:
[0034] The inflammatory bowel disease efficacy screening process described in the present invention includes the following steps: 1) induction and differentiation of macrophage-containing colon organoids, passage and amplification, and quality inspection of the amplified products; 2) IBD modeling and model quality inspection; 3) IBD efficacy evaluation. This process establishes a complete IBD efficacy screening process based on colon organoids with functional macrophages. It can evaluate and screen IBD efficacy through multiple pathological indicators such as inhibiting inflammatory response, restoring mucus content, and repairing damaged barriers. It is suitable for the precise preclinical evaluation of IBD candidate drugs to improve the success rate of new drug development and shorten the research and development cycle. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] The accompanying drawings constituting a part of the present invention are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the accompanying drawings:
[0036] Figure 1 Flow cytometry was used to analyze the cellularity of colon organoid samples at day 7 of passage P5 for amplicon quality assurance; SATB2 + A marker for colon epithelial cells; MUC2 + Goblet cell marker; CD68 + It is a macrophage marker; duplicate wells n=4;
[0037] Figure 2Fluorescence quantitative PCR was used to analyze the relative expression levels of IBD pathological marker genes for quality identification of IBD models; both groups contained 3 replicate wells, each containing 40-50 colon organoids; β-CAT was an epithelial cell marker; TNF-α was an inflammatory factor marker; MUC2 was a mucin marker; **, P < 0.01;
[0038] Figure 3 For IBD drug efficacy screening; A and B are ESLIA determination of inflammation inhibition effect, the analysis samples are culture supernatants of 3 groups, n=4 replicates, each well containing 40-50 colon organoids; **, P<0.01; ***, P<0.001; C is PAS staining analysis of mucus recovery, the analysis samples are colon organoids of 3 groups, the statistical number of slices n=18, from n=3 replicates, each well containing 40-50 colon organoids; **, P<0.01; ***, P<0.001; D is β-CAT immunohistochemistry analysis of epithelial barrier repair, the statistical number of slices n=18, from n=3 replicates, each well containing 40-50 colon organoids; **, P<0.01; ***, P<0.001; The control group is a non-modeled sample; the modeling group is an IBD modeling sample; the drug group is an IBD modeling sample treated with IFX for 3 days. DETAILED DESCRIPTION
[0039] It should be noted that the following non-limiting examples are provided to further illustrate the invention disclosed by the present invention. It will be appreciated by those skilled in the art that the technical representatives disclosed in the following examples have found methods that work well in the practice of the present invention, and therefore can be considered as examples of the patterns that constitute them. However, according to the present invention, it will be appreciated by those skilled in the art that many changes can be made to the disclosed particular aspects and still the same or similar results can be obtained without departing from the spirit and scope of the present invention.
[0040] Definitive endoderm: refers to the original development site of the main cells of internal organs such as the liver, small intestine, and large intestine in the early stage of embryonic development.
[0041] Derivatives of the hindgut (or derivatives of the anterior part of the gut): The gut refers to the strip of tissue that develops from the definitive endoderm in the early embryonic development. In vivo studies have shown that its anterior and posterior ends are composed of different progenitor cells, which can develop into different organs. Among them, the colon develops from the progenitor cell group near the posterior end of the gut, which is developmentally called the hindgut or posterior part of the gut.
[0042] Multi-lineage colon organoids: Refers to colon organoids with physiologically relevant cell types.
[0043] The method for inducing differentiation of macrophage-containing colon organoids of the present invention comprises the following steps:
[0044] 1. Inducing differentiation
[0045] Stage 1: Induced pluripotent stem cells produce endoderm and a small part of mesoderm
[0046] hPSCs are cultured in culture medium 1a and culture medium 1b for 1-2 days, preferably cultured in culture medium 1a for 1 day and cultured in culture medium 1b for 2 days;
[0047] Medium 1a was supplemented with BMP4 and ActA, and Medium 1b was supplemented with ActA and FGF2. Medium 1a and Medium 1b also included RPMI-1640 containing 2% (volume ratio) B27;
[0048] The concentration of BMP4 can be 20-50 ng / ml, within which the objectives of the present invention can be achieved, and specifically 50 ng / ml can be used;
[0049] The concentration of ActA can be 100-120 ng / ml, within which the objectives of the present invention can be achieved, and specifically 100 ng / ml can be used;
[0050] The concentration of FGF2 can be 5-10 ng / ml, and the objectives of the present invention can be achieved within this range. Specifically, 10 ng / ml can be used.
[0051] Stage 2: Production of hindgut derivatives
[0052] The cells are cultured in culture medium 2 for 6-7 days, specifically 6 days; culture medium 2 is supplemented with VEGF and SCF, the VEGF concentration can be 10-20 ng / ml, within this range the objectives of the present invention can be achieved, specifically 10 ng / ml can be used; the SCF concentration can be 5-15 ng / ml, within this range the objectives of the present invention can be achieved, specifically 5 ng / ml can be used.
[0053] At this stage, VEGF and SCF are important inducing molecules. Adding VEGF and SCF simultaneously to the existing culture medium can increase the expression of hematopoietic progenitor cell markers CD146 and CD43, and promote the differentiation of hematopoietic progenitor cells. The solution given in this embodiment is only a better one among many solutions.
[0054] More specifically, FGF4 and Wnt / β-CAT activator can be added to culture medium 2, and the Wnt / β-CAT activator is one of CHIR99021 and Wnt3a, but is not always limited thereto, and specifically can be preferably CHIR99021; the concentration of FGF4 can be 250-500 ng / ml, within this range the objectives of the present invention can be achieved, and specifically 500 ng / ml can be used; the concentration of Wnt / β-CAT activator can be 1-5 μM, within this range the objectives of the present invention can be achieved, and specifically 3 μM can be used.
[0055] To ensure the formation of macrophages, culture medium 2 also used hematopoietic cell culture medium StemPro-34 at a volume ratio of 21.25%-42.5%.
[0056] Specifically, Medium 2 contained 2% (volume ratio) B27, 0.5% (volume ratio) N2, 55% (volume ratio) DMEM-F12PLUS, and 42.5% (volume ratio) StemPro-34.
[0057] After differentiation into the mid-posterior derivatives of the intestinal tube with hematopoietic progenitor cells, the upper layer of 3D spheres was discarded and the lower layer of 2D cells was mechanically disrupted using a pipette tip to form clumps of 100-300um in size.
[0058] Mechanical crushing methods are:
[0059] 1) Scraping: Discard the old culture medium together with the upper 3D spheroids, add preheated DMEM / F12 culture medium, and place the pipette tip perpendicular to the culture well. Draw lines 10-15 times in the up-down and left-right directions to transfer the formed cell clusters and culture medium intact to the EP tube.
[0060] 2) Blow and break: Place the pipette against the bottom of the EP tube and gently blow 3-5 times to form cell clumps of 100-300uM in size.
[0061] After centrifugation and resuspension in pre-cooled Matrigel, the cells were coated in cell culture plates and differentiation was continued using medium S3.
[0062] Stage 3: Generation of macrophage-containing colon organoids
[0063] Sequentially culturing in medium 3a for 3-4 days and in medium 3b for 24-59 days (preferably 28-29 days), preferably culturing in medium 3a for 3 days and in medium 3b for 28 days;
[0064] Specifically, culture medium 3a contains additives BMP2, EGF, Wnt / β-CAT activator and StemPro-34 in a volume ratio of 21.25%-42.5%, and culture medium 3b contains additives EGF, VEGF, M-CSF, BMP inhibitor, Wnt / β-CAT activator and StemPro-34 in a volume ratio of 17.5-35%;
[0065] At this stage, VEGF and M-CSF are important inducing molecules. Adding VEGF and M-CSF simultaneously to the existing culture medium can promote the differentiation and formation of macrophages. The solution given in this embodiment is only a better one among many solutions.
[0066] In addition, the continuous addition of StemPro-34 into S2 and S3 and the concentration are also key to the present invention. The concentration scheme given in this example is only a better one among many schemes.
[0067] The concentration of BMP2 can be 50-150 ng / ml, within which the objectives of the present invention can be achieved, and specifically 100 ng / ml can be used;
[0068] The EGF concentration can be 50-150 ng / ml, within which the objectives of the present invention can be achieved, and specifically 100 ng / ml can be used;
[0069] The Wnt / β-CAT activator is one of CHIR99021 and Wnt3a, but is not always limited thereto, and may be preferably CHIR99021; the concentration of the Wnt / β-CAT activator may be 2-4 μM, within which the objectives of the present invention may be achieved, and specifically, the concentration in culture medium 3a is 3 μM, and the concentration in culture medium 3b is 2 μM.
[0070] The VEGF concentration can be 10-20 ng / ml, within which the objectives of the present invention can be achieved, and specifically 20 ng / ml can be used;
[0071] The concentration of M-CSF can be 10-20 ng / ml, within which the objectives of the present invention can be achieved, and specifically 10 ng / ml can be used;
[0072] The BMP inhibitor is one of LDN193189, NOG, and BML-275, but is not always limited thereto, and may be preferably LDN193189; the concentration of the BMP inhibitor may be 100-250 nM, and the objective of the present invention may be achieved within this range, and may be specifically 200 nM.
[0073] Specifically, medium 3a also contained 2% (volume ratio) B27, 0.5% (volume ratio) N2, 55% (volume ratio) DMEM-F12 PLUS, and 42.5% (volume ratio) StemPro-34;
[0074] Medium 3b also contained 2% (volume) B27, 0.5% (volume) N2, 80% (volume) DMEM-F12 Plus, and 17.5% (volume) StemPro-34.
[0075] 2. Serial passage and expansion of colon organoids
[0076] After the formed organoids are transferred to EP tubes, they are mechanically broken into 100-300 μm clumps using a pipette tip; after being coated with matrix gel again, they are pre-cultured with culture medium 3a for 1 day, and then cultured with culture medium 3b; they are subcultured every 7-10 days at a ratio of 1:5-1:10, and pre-culture is performed for each subculture.
[0077] The invention will be described in detail below with reference to the accompanying drawings and embodiments.
[0078] The relevant reagents used in the examples are shown in Tables 1 and 2, the relevant primers are shown in Table 3, and the relevant antibodies used are shown in Table 4.
[0079] Example 1 Induction of differentiation, passage and expansion of macrophage-containing colonic organoids and quality assessment of amplified products
[0080] 1. Inducing differentiation
[0081] Stage 1: Induction of endoderm and a small amount of mesoderm (Days 1-3)
[0082] When the confluence of hPSCs reaches 80-95%, differentiation can be initiated.
[0083] 1.1 Day 1
[0084] The cells were cultured for 1 day in medium 1a, which contained the additives 50 ng / ml BMP4, 100 ng / ml ActA, and RPMI-1640 containing 2% (v / v) B27.
[0085] 1.2 Days 2-3
[0086] Culture was continued for 2 days in medium 1b containing supplements 100 ng / ml ActA, 10 ng / ml FGF2, and RPMI-1640 containing 2% (v / v) B27, with medium replacement daily.
[0087] Stage 2: Generation of midgut derivatives with hematopoietic progenitor cells (Days 4-9)
[0088] Culture was continued for 6 days in medium 2, which included additives 500 ng / ml FGF4, 3 μM CHIR99021, 10 ng / ml VEGF, 5 ng / ml SCF, and 2% (volume ratio) B27, 0.5% (volume ratio) N2, 55% (volume ratio) DMEM-F12PLUS, and 42.5% (volume ratio) StemPro-34, during which the medium was changed daily.
[0089] At the end of day 9, the upper 3D spheres were discarded and the lower 2D cells were mechanically disrupted using a pipette tip to form clumps of 100-300 μm in size.
[0090] Mechanical crushing methods are:
[0091] 1) Scraping: Discard the old culture medium together with the upper 3D spheroids, add preheated DMEM / F12 culture medium, and place the pipette tip perpendicular to the culture well to draw lines 10 times in the up-down and left-right directions to transfer the formed cell clusters and culture medium intact into the EP tube.
[0092] 2) Blow and break: Place the pipette against the bottom of the EP tube and gently blow 3-5 times to form cell clumps of 100-300uM in size.
[0093] After centrifugation and resuspension in pre-cooled Matrigel, the cells were coated in cell culture plates and differentiation was continued using medium S3.
[0094] Stage 3: Induction of macrophage-containing colonic organoids (Days 10-40)
[0095] 3.1: Day 10-12
[0096] The cells were cultured for 3 days in medium 3a, which included additives such as 100 ng / ml BMP2, 100 ng / ml EGF, 3 μM CHIR99021, and 2% (volume ratio) B27, 0.5% (volume ratio) N2, 55% (volume ratio) DMEM-F12 PLUS, and 42.5% (volume ratio) StemPro-34. The medium was not changed during this period.
[0097] 3.2: Days 13-40
[0098] Culture was continued for 28 days in medium 3b, which included the supplements 100 ng / ml EGF, 20 ng / ml VEGF, 10 ng / ml M-CSF, 200 nM LDN193189, 2 μM CHIR99021, as well as 2% (volume ratio) B27, 0.5% (volume ratio) N2, 80% (volume ratio) DMEM-F12 Plus, and 17.5% (volume ratio) StemPro-34.
[0099] During this period, the culture medium was changed every 3 days; by day 40, lineage specification was complete and macrophage-containing colon organoids were formed.
[0100] 2. Subculture and amplification
[0101] After the organoids formed on the 40th day were transferred to EP tubes, they were mechanically broken into 100-300 μm clumps using a pipette tip; they were coated with matrix gel again, pre-cultured with culture medium 3a for 1 day, and then continued to use culture medium 3b; they were subcultured every 7-10 days at a ratio of 1:5-1:10, and pre-culture was performed for each subculture.
[0102] 3. Quality verification of amplified products
[0103] Expanded organoids were taken and lineage diversity was confirmed by flow cytometry or immunofluorescence staining.
[0104] Specifically, the flow cytometry method is as follows: the amplified product is digested and dispersed into single cells using TrypLE, and fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton, and blocked with 5% normal donkey serum. After that, the cell number is analyzed using a flow cytometer after labeling and staining based on specific marker antibodies.
[0105] The immunofluorescence staining method is: fix with 4% paraformaldehyde, permeabilize with 0.1% Triton, block with 5% normal donkey serum, then label and stain with specific marker antibodies, and take pictures with a laser confocal microscope.
[0106] Interpretation of results: When the organoids have colon epithelial cells, mesenchymal cells and intestinal resident macrophages, they are considered to have passed the test. Specifically, these cells include: STAB2 + Colonic epithelial cells, MUC2 + Goblet cells and CD68 + Macrophages.
[0107] Example 2 IBD modeling and model quality verification
[0108] 1. IBD modeling
[0109] Plate setup, organoid seeding, and IBD modeling:
[0110] After the organoids pass the inspection, the control group, modeling group and its subgroups are set up based on the type of drug tested, and 30-50 organoids / well × 3-5 replicate wells are inoculated; in addition, each group has an additional 3-5 replicate wells for model quality identification.
[0111] PBS and DSS (dextran sulfate sodium) were added to the culture medium of the control group and the modeling group respectively, and the treatment was continued for 4 days, and the new culture medium was replaced every 2 days. The mass concentration of DSS was 0.005-0.015%, and the objectives of the present invention could be achieved within this range. In this embodiment, 0.005% was specifically used.
[0112] 2. Quality inspection
[0113] Analytical methods:
[0114] Organoids from the control group and the modeling group were taken, and total RNA was extracted using Trizol RNA extraction agent, and the fluorescence quantitative Q-PCR method was used to detect and analyze the expression levels of IBD pathological markers.
[0115] Specifically, IBD pathological markers include the relative expression levels of the epithelial marker β-CAT, the inflammatory factor TNF-α, and the mucin marker MUC2.
[0116] Result interpretation:
[0117] Indicator 1-epithelial to mesenchymal transition: When β-CAT expression was significantly reduced (P value between groups < 0.05), it indicated that the epithelial barrier was damaged.
[0118] Indicator 2-Increased inflammation level: When TNF-α expression is significantly increased (P value between groups < 0.05), it indicates an increase in inflammation level.
[0119] Indicator 3-reduced mucus level: When MUC2 expression was significantly reduced (P value between groups < 0.05), it indicated that the mucus level was reduced.
[0120] When indicators 1-3 all showed statistical differences between groups, the model was considered to have passed the quality test.
[0121] Example 3 IBD drug efficacy screening
[0122] After the model passes the inspection, a drug group is set up based on the previously set drug treatment subgroups, and the test drug is added to the culture medium of the inspected modeling group. The treatment is continued for 3-7 days, and the following indicators are selected to evaluate the IBD drug efficacy.
[0123] In this example, IFX (Infliximab) was used as an example for drug efficacy testing, and 200 ng / ml IFX was treated for 3 days.
[0124] Indicator 1-Inhibition of inflammatory response: Organoids from the control group, modeling group, and drug group were taken, and the secretion of IBD-related inflammatory factors in the supernatant was detected by ELISA (enzyme-linked immunosorbent assay). Optionally, inflammatory factors include TNF-α, IL-6, IL-23, and IL-33. The method follows the operating instructions of the corresponding kit.
[0125] Interpretation of results: When the inflammatory factors in the drug group were significantly less than those in the modeling group (P value between groups < 0.05), it was considered to be effective in inhibiting inflammation.
[0126] Indicator 2 - Restoration of mucus content: Analysis of mucus content by PAS staining of pathological sections. Methods: Follow the instructions of the PAS staining kit and use ImageJ software for quantitative analysis based on the stained area.
[0127] Interpretation of results: When the PAS-positive area in the drug group was significantly less than that in the modeling group (P value between groups < 0.05), it was considered to be effective in mucus recovery.
[0128] Indicator 3-Repair of damaged barrier: The β-CAT positivity rate was detected by staining of pathological sections and quantitative analysis was performed using ImageJ software.
[0129] Interpretation of results: When the β-CAT staining positive area in the drug group was significantly higher than that in the modeling group (P value between groups < 0.05), it was considered to be effective in barrier repair.
[0130] Based on the above efficacy analysis results, if it is determined that there is an IBD efficacy, subsequent analysis and verification such as target verification and specificity verification can be carried out according to the drug targets and corresponding molecular mechanisms.
[0131] Results and analysis:
[0132] 1. After induction of differentiation and passage amplification to P5, quality inspection was performed; flow cytometry analysis results showed that the amplified product contained about 87.4% of STAB2 + Colon epithelial cells, 28.8% MUC2 + Goblet cells, and 7.13% CD68 + Macrophage composition ( Figure 1 ), so the quality of the expanded organoids was tested.
[0133] 2. After inoculation and modeling, the inspected organoids will undergo quality inspection.
[0134] like Figure 2As shown, the results of fluorescence quantitative PCR detection were as follows: compared with the control group, the expression of β-CAT in the modeling group was significantly decreased, indicating epithelial damage; the expression of TNF-α was significantly increased, indicating an increase in the level of inflammation; the expression of MUC2 was significantly decreased, indicating a decrease in mucus levels; the above results showed that the modeling was successful and passed the model quality inspection.
[0135] 3. After 3 days of treatment with 200ng / ml IFX, the ELISA results showed that ( Figure 3 A and 3B): IFX significantly reduced the secretion of IL-6 and TNF-α in the model group, indicating that it has an inhibitory effect on inflammation. The results of PAS staining quantitative analysis showed that ( Figure 3 C): Compared with the modeling group, the PAS of the drug group + The positive area increased significantly, indicating that IFX has an effect on the recovery of mucus content. The results of quantitative immunohistochemical analysis showed that ( Figure 3 D): Drug group β-CAT + The positive cells increased significantly, indicating that IFX has the effect of repairing the epithelial barrier.
[0136] Table 1 Reagent list
[0137]
[0138] Table 2 Corresponding names of reagents
[0139]
[0140] Table 3 Primer list
[0141]
[0142] Table 4 Antibody list
[0143]
[0144] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for screening drug efficacy for inflammatory bowel disease, characterized in that: The method comprises the following steps: 1) Construction of macrophage-containing colon organoids Induce pluripotent stem cells to differentiate into the middle and posterior derivatives of the intestinal tube with hematopoietic progenitor cells, then select the lower layer 2D cells for mechanical disruption, and then encapsulate them in Matrigel and use medium 3a and medium 3b to continue differentiation to form colon organoids; The obtained organoids were then transferred to EP tubes and mechanically broken, and then coated with matrix gel again, and then pre-cultured with culture medium 3a, and then continued to be cultured with culture medium 3b, and subcultured every 7-10 days at a ratio of 1:5-1:10; the expanded and cultured organoids were then tested to verify that the organoids contained colon epithelial cells, mesenchymal cells, and intestinal resident macrophages; Among them, the organoids were pre-cultured in culture medium 3a for 1-2 days after mechanical disruption; culture medium 3a included BMP2, EGF, Wnt / β-CAT activator and StemPro-34, and culture medium 3b included EGF, BMP inhibitor, Wnt / β-CAT activator, VEGF, M-CSF and StemPro-34; the concentration of BMP2 was 50-150ng / ml, the concentration of EGF was 50-150ng / ml, the concentration of Wnt / β-CAT activator was 2-4μM, the concentration of BMP inhibitor was 100-250nM, the concentration of VEGF was 10-20ng / ml, and the concentration of M-CSF was 10-20ng / ml; the volume ratio of StemPro-34 in culture medium 3a was 21.25%-42.5%, and the volume ratio in culture medium 3b was 17.5-35%; 2) IBD modeling and testing A control group and a modeling group were set up, and PBS and sodium dextran sulfate were added to the culture medium of the control group and the modeling group, respectively, to treat the modeling. The expression level of IBD pathological markers was detected and analyzed using the fluorescent quantitative Q-PCR method to verify the success of the modeling; the mass concentration of sodium dextran sulfate was 0.005-0.015%, and the treatment time was 4-6 days; 3) IBD drug efficacy screening A drug group was set up, that is, the test drug was added to the culture medium of the tested modeling group, and the treatment was continued for 3-7 days. The IBD efficacy was evaluated by detecting one or more of the inhibition of inflammatory response, restoration of mucus content, and repair of damaged barriers. When the P value between groups was <0.05, it was determined that there was an IBD efficacy.
2. The method for screening drug efficacy for inflammatory bowel disease according to claim 1, characterized in that: In step 1), organoids are characterized by flow cytometry or immunofluorescence staining to confirm lineage diversity.
3. The method for screening drug efficacy for inflammatory bowel disease according to claim 1, characterized in that: In step 2), 30-50 organoids / well were inoculated in both the control group and the modeling group; in addition, 3-5 additional replicate wells were set up in both groups for model quality verification.
4. The method for screening drug efficacy for inflammatory bowel disease according to claim 1, characterized in that: In step 2), IBD pathological markers include the epithelial marker β-CAT, the inflammatory factor TNF-α, and the mucin marker MUC2.
5. The method for screening drug efficacy for inflammatory bowel disease according to claim 4, characterized in that: IBD pathological markers were evaluated as follows: 1) Epithelial to mesenchymal transition: When β-CAT expression is significantly reduced, that is, the inter-group P value is less than 0.05, it indicates that the epithelial barrier is damaged; 2) Increased inflammation level: When TNF-α expression is significantly increased, that is, the inter-group P value is less than 0.05, it indicates that the inflammation level is increased; 3) Decreased mucus level: When MUC2 expression is significantly reduced, that is, the P value between groups is less than 0.05, it indicates that the mucus level is reduced; When the above three evaluations showed statistical differences among the groups, the model was considered to have passed the quality test.
6. The method for screening drug efficacy for inflammatory bowel disease according to claim 1, characterized in that: Evaluation of IBD drug efficacy specifically includes the following: 1) The evaluation method for inhibiting inflammatory response is as follows: the organoids of the control group, model group, and drug group are taken, and the secretion of IBD-related inflammatory factors in the supernatant is detected by ELISA enzyme-linked immunosorbent assay. When the inflammatory factors in the drug group are significantly less than those in the model group, that is, the inter-group P value is <0.05, it is considered to be effective in inhibiting inflammation; 2) The evaluation method for restoring mucus content is: analyzing the mucus content by PAS pathological section staining, and using ImageJ software for quantitative analysis based on the staining area; when the PAS staining positive area in the drug group is significantly less than that in the modeling group, that is, the inter-group P value is <0.05, it is considered to be effective in mucus recovery; 3) The evaluation method for repairing the damaged barrier is: detecting the β-CAT positivity rate by staining pathological sections and using ImageJ software for quantitative analysis; when the β-CAT staining positive area in the drug group is significantly higher than that in the modeling group, that is, the inter-group P value is <0.05, it is considered to be effective in barrier repair.
7. The method for screening drug efficacy for inflammatory bowel disease according to claim 6, characterized in that: Inflammatory factors include one or more of TNF-α, IL-6, IL-23, and IL-33.
